Bioventus Inc (BVS)

Bioventus Inc - (BVS) Price Target Increased by 40.00% to 3.57 - MSN

MSN

Bioventus (NYSE:BVS) Shares Up 4.4% - MarketBeat

MarketBeat

Here's Why You Should Retain Centene (CNC) Stock for Now

Zacks Investment Research

Bioventus (NYSE:BVS) Releases FY 2024 Earnings Guidance - MarketBeat

MarketBeat

Bioventus (NYSE:BVS) Price Target Increased to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat

MarketBeat

Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant Growth and Improved ... - GuruFocus.com

GuruFocus.com

Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Bioventus (NYSE:BVS) Price Target Increased to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat

MarketBeat

Bioventus gains after raising annual sales, profit forecasts - XM

XM

Bioventus Reports First Quarter Financial Results - 07.05.2024 - wallstreet:online

wallstreet:online

Bioventus stock target increased on Q1 performance By Investing.com - Investing.com

Investing.com

Bioventus (BVS) to Release Earnings on Tuesday - Defense World

Defense World

Bone and Joint Regenerative Medicines Market 2024 Segment Analysis | Anika Therapeutics Inc., Arthrex Inc., Baxter ... - Motions Online

Motions Online

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

GlobeNewswire Inc.

BVS Stock Quote Price and Forecast - CNN

CNN

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday

Benzinga

Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Bioventus, Inc. on the Brink: Navigating Financial Control Challenges and Investor Confidence - TipRanks.com - TipRanks

TipRanks

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday

Benzinga

Bioventus Surges with 7.6% Q4 Revenue Growth to $135.4M, Outstripping Expectations - The Tokenist

The Tokenist

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders ... - GlobeNewswire

GlobeNewswire

Bioventus: Bullish On Path To Profitability (NASDAQ:BVS) - Seeking Alpha

Seeking Alpha

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

GlobeNewswire Inc.

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

GlobeNewswire Inc.

Durham-based Bioventus names veteran life science exec as CEO - WRAL TechWire

WRAL TechWire

Bioventus Names Robert Claypoole as President and Chief Executive Officer

GlobeNewswire Inc.

MedTech Bioventus' Stabilization Sparks Analyst Confidence, Earns Upgrade And Price Target Boost

Benzinga

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee ... - OrthoSpineNews

OrthoSpineNews

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

GlobeNewswire Inc.

Smith+Nephew steps up with $330M acquisition of Cartiheal - BioWorld Online

BioWorld Online

Smith+Nephew swoops in with $330M offer for CartiHeal after Bioventus bows out - Fierce Biotech

Fierce Biotech

Bioventus Stock: Improving Outlook Keeps It Interesting (NASDAQ:BVS) - Seeking Alpha

Seeking Alpha

Juniper Investment Company, LLC Increases Stake in Bioventus Inc - Yahoo Finance

Yahoo Finance

Reed Smith represents Bioventus in sale of its wound business to LifeNet Health | Neuigkeiten - Reed Smith LLP

Reed Smith LLP

Over $1M Bet On Bioventus? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Markets Insider

Markets Insider

Bioventus completes wound business divestiture - Mass Device

Mass Device

LifeNet Health acquires best-in-class wound care portfolio - PR Newswire

PR Newswire

Chancery Trims Suit Over $110M Bioness-Bioventus Deal - Law360

Law360

Bioventus unseats CEO as CartiHeal deal falls apart - Fierce Biotech

Fierce Biotech

Bioventus Appoints Anthony Bihl As Interim CEO - citybiz

citybiz

Is Bioventus Backing Out of CartiHeal Deal? - https://ryortho.com/

https://ryortho.com/

Smith & Nephew profits shrink amid major fall in Bioventus shareholding - This is Money

This is Money

Pomerantz Law Firm Announces the Filing of a Class Action Against Bioventus Inc. and Certain Officers and Directors ... - PR Newswire

PR Newswire

Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses - GlobeNewswire

GlobeNewswire

Why Shares of Bioventus Fell 14% on Wednesday - The Motley Fool

The Motley Fool

Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight - GlobeNewswire

GlobeNewswire

Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript - The Motley Fool

The Motley Fool

Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan - Fierce Biotech

Fierce Biotech